| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer.
|
N Engl J Med
|
2010
|
8.10
|
|
2
|
Gene expression programs in response to hypoxia: cell type specificity and prognostic significance in human cancers.
|
PLoS Med
|
2006
|
6.04
|
|
3
|
Gene expression patterns in ovarian carcinomas.
|
Mol Biol Cell
|
2003
|
2.55
|
|
4
|
Uterine sarcomas in Norway. A histopathological and prognostic survey of a total population from 1970 to 2000 including 419 patients.
|
Histopathology
|
2009
|
1.91
|
|
5
|
PIK3CA mutations in advanced ovarian carcinomas.
|
Hum Mutat
|
2005
|
1.61
|
|
6
|
Deregulation of MYCN, LIN28B and LET7 in a molecular subtype of aggressive high-grade serous ovarian cancers.
|
PLoS One
|
2011
|
1.57
|
|
7
|
Quality of pathology reports for advanced ovarian cancer: are we missing essential information? An audit of 479 pathology reports from the EORTC-GCG 55971/NCIC-CTG OV13 neoadjuvant trial.
|
Eur J Cancer
|
2010
|
1.57
|
|
8
|
Gene expressions and copy numbers associated with metastatic phenotypes of uterine cervical cancer.
|
BMC Genomics
|
2006
|
1.37
|
|
9
|
Presence of E6 and E7 mRNA from human papillomavirus types 16, 18, 31, 33, and 45 in the majority of cervical carcinomas.
|
J Clin Microbiol
|
2006
|
1.36
|
|
10
|
Apolipoprotein E is required for cell proliferation and survival in ovarian cancer.
|
Cancer Res
|
2005
|
1.22
|
|
11
|
Granulin-epithelin precursor is a novel prognostic marker in epithelial ovarian carcinoma.
|
Cancer
|
2004
|
1.22
|
|
12
|
Gene dosage, expression, and ontology analysis identifies driver genes in the carcinogenesis and chemoradioresistance of cervical cancer.
|
PLoS Genet
|
2009
|
1.19
|
|
13
|
GeneCount: genome-wide calculation of absolute tumor DNA copy numbers from array comparative genomic hybridization data.
|
Genome Biol
|
2008
|
1.18
|
|
14
|
Diagnosis and treatment of sarcoma of the uterus. A review.
|
Acta Oncol
|
2012
|
1.16
|
|
15
|
EMMPRIN (extracellular matrix metalloproteinase inducer) is a novel marker of poor outcome in serous ovarian carcinoma.
|
Clin Exp Metastasis
|
2003
|
1.13
|
|
16
|
Postradiotherapy morbidity in long-term survivors after locally advanced cervical cancer: how well do physicians' assessments agree with those of their patients?
|
Int J Radiat Oncol Biol Phys
|
2008
|
1.10
|
|
17
|
The clinical significance of EphA2 and Ephrin A-1 in epithelial ovarian carcinomas.
|
Gynecol Oncol
|
2005
|
1.09
|
|
18
|
The prognostic impact of EphB2/B4 expression on patients with advanced ovarian carcinoma.
|
Gynecol Oncol
|
2006
|
1.09
|
|
19
|
Expression of p27, p21, and p16 protein in early squamous cervical cancer and its relation to prognosis.
|
Gynecol Oncol
|
2003
|
1.06
|
|
20
|
beta-catenin expression, DNA ploidy and clinicopathological features in ovarian cancer: a study in 253 patients.
|
Eur J Cancer
|
2005
|
1.06
|
|
21
|
Prognostic value of EphA2 and EphrinA-1 in squamous cell cervical carcinoma.
|
Gynecol Oncol
|
2004
|
1.03
|
|
22
|
Hypoxia-induced gene expression in chemoradioresistant cervical cancer revealed by dynamic contrast-enhanced MRI.
|
Cancer Res
|
2012
|
1.02
|
|
23
|
Protein expression and prognostic value of genes in the erb-b signaling pathway in advanced ovarian carcinomas.
|
Am J Clin Pathol
|
2005
|
0.99
|
|
24
|
Metabolic mapping by use of high-resolution magic angle spinning 1H MR spectroscopy for assessment of apoptosis in cervical carcinomas.
|
BMC Cancer
|
2007
|
0.98
|
|
25
|
Proteomic analysis of malignant ovarian cancer effusions as a tool for biologic and prognostic profiling.
|
Clin Cancer Res
|
2006
|
0.97
|
|
26
|
Identification of eight candidate target genes of the recurrent 3p12-p14 loss in cervical cancer by integrative genomic profiling.
|
J Pathol
|
2013
|
0.95
|
|
27
|
High sensitivity assays for docetaxel and paclitaxel in plasma using solid-phase extraction and high-performance liquid chromatography with UV detection.
|
BMC Clin Pharmacol
|
2006
|
0.94
|
|
28
|
Effect of the codon 72 polymorphism (c.215G>C, p.Arg72Pro) in combination with somatic sequence variants in the TP53 gene on survival in patients with advanced ovarian carcinoma.
|
Hum Mutat
|
2004
|
0.91
|
|
29
|
Intratumor chromosomal heterogeneity in advanced carcinomas of the uterine cervix.
|
Int J Cancer
|
2004
|
0.90
|
|
30
|
Variation in gene expression patterns in effusions and primary tumors from serous ovarian cancer patients.
|
Mol Cancer
|
2005
|
0.89
|
|
31
|
Expression of xeroderma pigmentosum A protein predicts improved outcome in metastatic ovarian carcinoma.
|
Cancer
|
2005
|
0.89
|
|
32
|
The clinical role of the PEA3 transcription factor in ovarian and breast carcinoma in effusions.
|
Clin Exp Metastasis
|
2004
|
0.88
|
|
33
|
Membranous expression of ectodomain isoforms of the epidermal growth factor receptor predicts outcome after chemoradiotherapy of lymph node-negative cervical cancer.
|
Clin Cancer Res
|
2011
|
0.88
|
|
34
|
Pharmacokinetic parameters derived from dynamic contrast enhanced MRI of cervical cancers predict chemoradiotherapy outcome.
|
Radiother Oncol
|
2013
|
0.88
|
|
35
|
Beta-catenin expression in uterine sarcomas and its relation to clinicopathological parameters.
|
Eur J Cancer
|
2009
|
0.87
|
|
36
|
Long-term outcomes after pelvic radiation for early-stage endometrial cancer.
|
J Clin Oncol
|
2013
|
0.87
|
|
37
|
The sexual activity questionnaire: pychometric properties and normative data in a norwegian population sample.
|
J Womens Health (Larchmt)
|
2007
|
0.86
|
|
38
|
Risk grouping in stage IB squamous cell cervical carcinoma.
|
Gynecol Oncol
|
2005
|
0.85
|
|
39
|
Dynamic contrast-enhanced MRI of cervical cancers: temporal percentile screening of contrast enhancement identifies parameters for prediction of chemoradioresistance.
|
Int J Radiat Oncol Biol Phys
|
2011
|
0.84
|
|
40
|
Late effects after radiotherapy for locally advanced cervical cancer: comparison of two brachytherapy schedules and effect of dose delivered weekly.
|
Int J Radiat Oncol Biol Phys
|
2009
|
0.83
|
|
41
|
Prognostic significance of dysadherin expression in cervical squamous cell carcinoma.
|
Pathol Oncol Res
|
2004
|
0.83
|
|
42
|
Caveolin-1 expression in ovarian carcinoma is MDR1 independent.
|
Am J Clin Pathol
|
2002
|
0.83
|
|
43
|
Pharmacokinetic analysis and k-means clustering of DCEMR images for radiotherapy outcome prediction of advanced cervical cancers.
|
Acta Oncol
|
2011
|
0.82
|
|
44
|
E-cadherin and catenins in early squamous cervical carcinoma.
|
Gynecol Oncol
|
2004
|
0.82
|
|
45
|
High levels of genomic aberrations in serous ovarian cancers are associated with better survival.
|
PLoS One
|
2013
|
0.82
|
|
46
|
Interleukin-8 and vascular endothelial growth factor mRNA and protein levels are down-regulated in ovarian carcinoma cells in serous effusions.
|
Clin Exp Metastasis
|
2002
|
0.82
|
|
47
|
The prognostic impact of cyclin dependent kinase inhibitors p21WAF1, p27Kip1, and p16INK4/MTS1 in adenocarcinomas of the uterine cervix: an immunohistochemical evaluation of expression patterns in population-based material from 142 patients with international federation of gynecology and obstetrics stage I and II adenocarcinoma.
|
Cancer
|
2003
|
0.81
|
|
48
|
Expressions of EphA2 and EphrinA-1 in early squamous cell cervical carcinomas and their relation to prognosis.
|
Int J Med Sci
|
2008
|
0.81
|
|
49
|
Human papillomavirus DNA and e6/e7 mRNA status in relation to survival of patients treated for cervical squamous cell carcinoma.
|
Open Virol J
|
2008
|
0.80
|
|
50
|
The prognostic value of adaptive nuclear texture features from patient gray level entropy matrices in early stage ovarian cancer.
|
Anal Cell Pathol (Amst)
|
2012
|
0.80
|
|
51
|
Quality of life of advanced ovarian cancer patients in the randomized phase III study comparing primary debulking surgery versus neo-adjuvant chemotherapy.
|
Gynecol Oncol
|
2013
|
0.80
|
|
52
|
European Network of Gynaecological Oncological Trial Groups' requirements for trials between academic groups and pharmaceutical companies.
|
Int J Gynecol Cancer
|
2010
|
0.79
|
|
53
|
Expression of the 67 kDa laminin receptor and the alpha6 integrin subunit in serous ovarian carcinoma.
|
Clin Exp Metastasis
|
2003
|
0.79
|
|
54
|
Cyclins and proliferation markers in early squamous cervical carcinoma.
|
Gynecol Oncol
|
2004
|
0.79
|
|
55
|
X chromosome inactivation in cervical cancer patients.
|
Cancer Genet Cytogenet
|
2003
|
0.79
|
|
56
|
Phosphorylation of EGFR measured with in situ proximity ligation assay: relationship to EGFR protein level and gene dosage in cervical cancer.
|
Radiother Oncol
|
2011
|
0.79
|
|
57
|
Intestinal malabsorption in long-term survivors of cervical cancer treated with radiotherapy.
|
Int J Radiat Oncol Biol Phys
|
2008
|
0.78
|
|
58
|
Entropy-based adaptive nuclear texture features are independent prognostic markers in a total population of uterine sarcomas.
|
Cytometry A
|
2014
|
0.78
|
|
59
|
Expression of 14-3-3sigma in cervical squamous cell carcinomas: relationship with clinical outcome.
|
Oncol Rep
|
2009
|
0.77
|
|
60
|
Genome profiles of bilateral dysgerminomas, a unilateral gonadoblastoma, and a metastasis from a 46, XY phenotypic female.
|
Hum Pathol
|
2003
|
0.75
|
|
61
|
Genomic imbalances in endometrial adenocarcinomas - comparison of DNA ploidy, karyotyping and comparative genomic hybridization.
|
Mol Oncol
|
2011
|
0.75
|
|
62
|
|
Tidsskr Nor Laegeforen
|
2017
|
0.75
|